CYTK
Cytokinetics Inc
NASDAQ: CYTK · HEALTHCARE · BIOTECHNOLOGY
$63.97
+7.37% today
Updated 2026-04-30
Market cap
$7.54B
P/E ratio
—
P/S ratio
85.64x
EPS (TTM)
$-6.54
Dividend yield
—
52W range
$29 – $71
Volume
1.9M
Cytokinetics Inc (CYTK) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-1,005.00%
ROE
-572.00%
ROA
-27.10%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $3.13M | $-57.12M | 100.00% | -1,961.56% | -1,826.51% |
| 2007 | $13.62M | $-48.89M | 100.00% | -414.67% | -358.93% |
| 2008 | $12.42M | $-56.37M | 100.00% | -475.68% | -453.90% |
| 2009 | $81.54M | $24.54M | 100.00% | 32.00% | 30.10% |
| 2010 | $2.58M | $-49.29M | 100.00% | -1,926.08% | -1,912.57% |
| 2011 | $4.00M | $-47.86M | 100.00% | -1,199.10% | -1,196.50% |
| 2012 | $7.56M | $-41.68M | -371.53% | -517.29% | -551.36% |
| 2013 | $30.65M | $-33.72M | -61.35% | -110.59% | -110.01% |
| 2014 | $46.94M | $-14.65M | 5.36% | -31.43% | -31.20% |
| 2015 | $28.66M | $-37.50M | -61.90% | -130.53% | -130.86% |
| 2016 | $106.41M | $16.45M | 43.71% | 17.56% | 15.46% |
| 2017 | $13.37M | $-127.79M | -575.46% | -848.26% | -955.94% |
| 2018 | $31.50M | $-106.29M | -182.96% | -282.26% | -337.41% |
| 2019 | $26.87M | $-121.69M | -220.55% | -367.97% | -452.93% |
| 2020 | $55.83M | $-127.29M | -73.66% | -168.27% | -228.00% |
| 2021 | $70.43M | $-215.31M | -127.09% | -264.54% | -305.72% |
| 2022 | $94.59M | $-388.95M | -154.59% | -342.75% | -411.21% |
| 2023 | $7.53M | $-526.24M | -4,284.10% | -6,589.71% | -6,988.63% |
| 2024 | $18.47M | $-589.53M | -1,737.22% | -2,902.72% | -3,191.11% |
| 2025 | $88.04M | $-784.96M | 88.50% | -695.44% | -891.60% |